Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma

Histone deacetylase 6 (HDAC6) is an attractive target for cancer therapeutic intervention. Selective HDAC6 inhibitors is important to minimise the side effects of pan inhibition. Thus, new class of hydroxamic acid-based derivatives were designed on structural basis to perform preferential activity a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Enzyme Inhib Med Chem
Main Authors: Kassab, Shaymaa E., Mowafy, Samar, Alserw, Aya M., Seliem, Joustin A., El-Naggar, Shahenda M., Omar, Nesreen N., Awad, Mohamed M.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6522981/
https://ncbi.nlm.nih.gov/pubmed/31072216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14756366.2019.1613987
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados